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Inflammatory bowel disease (IBD) is a chronic inflam-
matory disease thought to be mediated by dysfunc-
tional innate and/or adaptive immunity. This aberrant
immune response leads to the secretion of harmful
cytokines that destroy the epithelium of the gastroin-
testinal tract and thus cause further inflammation.
Interleukin-22 (IL-22) is a T helper 17 (Th17) T cell-
associated cytokine that is bifunctional in that it has
both proinflammatory and protective effects on tis-
sues depending on the inflammatory context. We
show herein that IL-22 protected mice from IBD. In-
terestingly, not only was this protection mediated
by CD4+ T cells, but IL-22-expressing natural killer
(NK) cells also conferred protection. In addition,
IL-22 expression was differentially regulated be-
tween NK cell subsets. Thus, both the innate and
adaptive immune responses have developed protec-
tive mechanisms to counteract the damaging effects
of inflammation on tissues.
INTRODUCTION
Interleukin-22 (IL-22) is a member of the IL-10-related family of
cytokines, which also include IL-19, IL-20, IL-24, and in humans,
IL-26, which are expressed during chronic inflammation. These
cytokines share 20%–30%amino acid identity and also have ho-
mologous secondary structures (Kotenko, 2002). IL-22 signals
through a heterodimeric receptor that consists of IL-22R and
IL-10Rb, whereas IL-10 signals through IL-10Ra and IL-10Rb
(Kotenko et al., 2001). Because IL-10Rb is ubiquitously ex-
pressed, signaling specificity is conferred by IL-10Ra and IL-22R
expression; IL-10Ra is limited to cells of the immune system,
whereas IL-22R expression is limited to tissue cells, such as ep-
ithelial cells (Wolk et al., 2004). Just as IL-10 protects the immune
system from overwhelming itself, IL-22 is proposed to protect
the tissues during inflammation via a signal transducer and acti-
vator of transcription 3 (Stat3)-mediated mechanism. IL-22 has
recently been shown to be protective during acute inflammation
in a hepatitis model (Radaeva et al., 2004; Zenewicz et al., 2007).
In contrast, IL-22 has been shown to mediate dermal inflamma-tion (Ma et al., 2008; Zheng et al., 2007). The dual nature of this
cytokine, protective versus inflammatory, probably depends on
the inflammatory context. This includes, but is not limited to,
the duration and amount of IL-22 present, the overall cytokine
milieu, and the involved tissues.
IL-22 is highly expressed by Th17 cells and is strongly linked to
chronic inflammation (Chung et al., 2006; Liang et al., 2006;
Zheng et al., 2007). Th17 cells were first defined by their expres-
sion of IL-17A but have since also been shown to preferentially
express IL-22, as well as IL-17F and IL-21 (Korn et al., 2007;
Liang et al., 2006; Nurieva et al., 2007; Weaver et al., 2006). In
mice, IL-23 was once thought to control Th17 differentiation,
but it now appears that its role is in survival and expansion of
Th17 cells (Aggarwal et al., 2003; Cua et al., 2003; Veldhoen
et al., 2006). Differentiation in mice appears to be directed by
the presence of both transforming growth factor-beta (TGF-b)
and inflammatory cytokines, such as IL-6 or IL-21, that activate
Stat3 signaling pathways in the T cells (Korn et al., 2007; Nurieva
et al., 2007; Veldhoen et al., 2006). However, it is becoming in-
creasingly apparent that the IL-22 expression profile differs
from that of IL-17A. Whereas TGF-b and IL-6 are both necessary
for induction of IL-17A, IL-22 can be induced via IL-6 alone, and
increasing amounts of TGF-b are actually inhibitory to its expres-
sion (Zheng et al., 2007 and our unpublished observations).
Inflammatory bowel disease (IBD) is a chronic inflammatory
disease of the gastrointestinal tract and is caused by aberrant in-
nate and/or adaptive immune responses (Podolsky, 2002). IBD
has long been described as a Th1-mediated disease because in-
terferon-gamma (IFN-g) is essential for disease progression
(Powrie et al., 1994b). However, the recent discovery of Th17
cells has led to a re-evaluation of the role of T cells in disease.
IL-23, important for the maintenance of Th17 cells, is essential
for development of IBD in mouse models (Kullberg et al.,
2006), and protective IL-23R polymorphisms in the human pop-
ulation have been identified through a genome association study
(Duerr et al., 2006). However, the role of individual Th17 cyto-
kines, such as IL-22, in IBD remains elusive. IL-22 has been
shown to be highly upregulated in the sera and in lesions of pa-
tients with either Crohn’s disease or ulcerative colitis (Andoh
et al., 2005). IL-22 can have proinflammatory effects on colon ep-
ithelial cells and induce secretion of IL-6 and IL-8, as well as ac-
tivate the transcription factors nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-kB) and activator protein-1
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IL-22 Protects from IBDexpression of IL-22 in the gastrointestinal tract by targeted
micro-injection is protective to colitis (Sugimoto et al., 2008).
However, it remains to be determined whether the immune re-
sponse itself has this protection mechanism during IBD.
In this study, we have investigated the role of IL-22 during IBD.
Using both innate and T cell-driven colitis animal models, we
have found a protective role for IL-22 during IBD. Our data sug-
gest that IL-22 secretion by not only CD4+ T cells but also, sur-
prisingly, NK cells in the colon mediates this protection.
RESULTS
Colon Epithelial Cells Are Responsive to IL-22
The IL-10-related cytokines (IL-10, IL-19, IL-20, IL-22, and IL-24)
share use of a family of heterodimeric cytokine receptors (Ko-
tenko, 2002; Moore et al., 2001). To begin to understand which
of these cytokines play a role in IBD, we compared expression
of the different receptor subunits in the gastrointestinal tract to
other tissues, such as the liver, spleen, and skin (Figure S1A in
the Supplemental Data available online). IL-10Ra, which is only
used by IL-10 and whose expression is primarily limited to im-
mune cells and not tissues, was highly expressed in the spleen
compared to other tissues. IL-10Rb, the b chain for both the
IL-10 and IL-22 receptor, was ubiquitously expressed in all tis-
sues, as previously reported. IL-22R, the a chain for the IL-22 re-
ceptor, was highly expressed in the colon and small intestine and
to a lesser extent in the other tissues we examined. We addition-
ally examined expression of IL-20Ra and IL-20Rb, which recog-
nize IL-19, IL-20, and IL-24, and found that both of these chains
were most highly expressed in the skin, which agrees with pub-
lished data indicating that these cytokines’ primary targets are
keratinocytes (Blumberg et al., 2001; Boniface et al., 2005).
The expression of the IL-22 receptor in the gut suggested that
the gastrointestinal system should be highly responsive to IL-22.
To further examine to which IL-10 family cytokine members co-
lon cells are responsive, and to confirm expression of the func-
tional receptor, we stimulated the human colon epithelial cell
line Caco-2 with recombinant human IL-10, IL-19, IL-20, or
IL-22. Upon recognition of the appropriate receptor, each of
these cytokines activates Stat3 in responsive cell types (Blum-
berg et al., 2001; Dumoutier et al., 2001; Dumoutier et al.,
2000). IL-22, but not IL-10, IL-19, or IL-20 induced detectable
phosphorylation of Stat3 (Figure S1B). Thus, colon epithelial
cells are a target for IL-22 activity.
IL-22 Is Induced in the Colon during IBD
To examine which cytokines are expressed during IBD in mice,
we used the CD45RBhi transfer model of colitis. This T cell-
dependent model involves the transfer of purified naive CD4
T cells (CD45RBhi) into Rag1/mice, which lack T cells (Morris-
sey et al., 1993; Powrie et al., 1994a). In the absence of both host
and regulatory T cells, these cells rapidly expand and gain effec-
tor functions, such as IFN-g secretion. In the absence of regula-
tory T cells, these functions are unchecked and result in massive
inflammation primarily of the gut, but eventually of other organs
such as the liver and skin. Five weeks after the transfer, when
mice had lost considerable body mass, we examined cytokine
expression in their inflamed colons. IFN-g has long been associ-
ated with IBD, and accordingly, we found that IFN-gmRNA was
highly induced in the inflamed colons compared to colons from
mice that did not receive T cells (Figure 1A). In contrast to IFN-g,
expression of Th17-associated cytokines is less well character-
ized; however, elevated IL-17A has been observed in several
other mouse models of IBD (Hue et al., 2006; Kullberg et al.,
2006). We found that both IL-22 and IL-17A mRNA were highly
expressed in the colons of Rag1/ mice that received naive
T cells (Figure 1A). A closer examination of the kinetics of the
induction of the mRNA of these cytokines revealed a 10- to
1000-fold increase in the amount of mRNA by 2 weeks after
the transfer, and this amount remained elevated throughout
the examined disease course (Figure 1B). In addition, when pu-
rified via FACS sorting, the population of transferred CD4+ T cells
recovered from the inflamed colons expressed mRNA for these
cytokines (data not shown). At the protein level, secreted IL-22,
as well as IFN-g, was detected in the supernatant of excised
colons cultured in vitro for 3 days (Figure 1C). Thus, IL-22 is
expressed during IBD in the colon, which includes a CD4+
T cell source.
IL-22 Is Protective during IBD
Because IL-22R is highly expressed in the gastrointestinal tract
and IL-22 expression is highly induced during inflammation of
these tissues, we sought to examine the role of IL-22 in IBD.
IL-22-deficient mice housed under specific-pathogen-free con-
ditions for up to one year did not develop spontaneous colitis,
indicating that IL-22 is not essential for maintenance of normal
intestinal homeostasis. We transferred IL-22-deficient or control
wild-type CD45RBhi CD4+ T cells into Il22/ Rag1/ double-
deficient mice. Over the course of several weeks, all mice that
received T cells developed colitis. However, mice that received
IL-22-deficient T cells had lost significantly more mass than
mice that received wild-type cells by 3 weeks after the transfer,
and a greater difference was observed at 4 weeks (Figure 2A)
(p value week 3 = 0.0367, week 4 = 0.0013). A significant differ-
encewas also observed at 5 and 6weeks after the transfer (week
5 p = 0.0134; week 6 p = 0.0389), and mice that received IL-22-
deficient cells had greater mortality (Figure S2). At 3 weeks after
the transfer, these mice had greater morphological changes in
their ascending colons, the main site of disease, as assessed
by histology (Figure 2B). No histopathology was noted in control
Il22/Rag1/ double-deficient mice that did not receive trans-
ferred cells (Figure 2B). Although in the absence of IL-22 there
was greater loss of body mass and destruction of the colonic
tissue, we observed little difference in cytokine expression
(Figure 2C); with the exception of IL-22, or the total number of in-
filtrated CD4+ T cells in the inflamed colon (Figure 2D), and these
observations agree with our previous data showing that IL-22-
deficient T cells do not have a defect in migration or cytokine
expression (Zenewicz et al., 2007). Thus, IL-22 is protective to
the colonic tissues during IBD.
Rag1/ Mice Express Protective IL-22
in the Colon during IBD
In addition toCD45RBhi CD4+T cell transfers into Il22/Rag1/
mice, we also performed experiments with Rag1/ mice as
recipients. Upon transfer of CD45RBhi Il22+/+ or Il22/ CD4+
T cells, these mice also developed colitis, as indicated by their
elevated amounts of both IFN-g and IL-17A mRNA in the colon948 Immunity 29, 947–957, December 19, 2008 ª2008 Elsevier Inc.
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IL-22 Protects from IBD(Figure 3A). Surprisingly, Rag1/ mice that received Il22/
CD4+ T cells also had detectable amounts of IL-22 mRNA and
protein in their colons (Figures 3A and 3B). The amount of IL-22
expressed in the colon was similar to that expressed by Il22+/+
CD4+ T cells when they were transferred into Il22/ Rag1/
mice, where the only source of IL-22 is the transferred T cells.
This suggests that there is a host-derived source of IL-22 during
IBD in Rag1/mice.
IL-22 expression, whether from transferred T cells or the host,
correlated with protection during IBD. Mice that completely
lacked IL-22 expression (Il22/ CD4+ T cells transferred into
Il22/ Rag1/ mice) had the most severe colitis. There was
no difference in disease, inferred from body-mass reduction, of
Rag1/ mice that received CD45RBhi Il22+/+ or Il22/ CD4+
T cells, in stark contrast to the difference observed when Il22/
Rag1/ mice were used as the hosts (Figure 3C). Thus, in
Rag1/ mice there is a cell subset(s) that expresses IL-22 in
the inflamed colon and is able to provide protection during IBD.
Differential Expression of IL-22 by NK Subsets
IL-22 expression is not limited to Th17 CD4+ T cells. Activated
NK cells, NK T cells, CD8+ T cells, and gd T cells can also express
IL-22 (Wolk et al., 2002; Zheng et al., 2007). Because Rag1/
mice lack CD4+ and CD8+ T cells, as well as NK T cells and gd
T cells, and because IL-22 is expressed in Rag1/mice, we hy-
pothesized that NK cells are responsible for the IL-22 expression
in the colons of the mice. We first wanted to better characterize
IL-22 expression by NK cells. There are different subsets of NK
cells, which in mice can be defined by CD27 expression (Haya-
kawa et al., 2006). Upon activation, CD27hi NK cells secrete
IFN-g and granzymes, and because of high expression of che-
mokine receptors, they quickly traffic to sites of inflammation.
On the other hand, CD27lo NK cells express high amounts of in-
hibitory receptors and upon stimulation express low levels of
IFN-g and granzymes; therefore, they are less cytotoxic than
CD27hi NK cells. To investigate which subset expresses IL-22
or whether both do, we purified NK cells based on their degree
of CD27 expression and then activated the cells with different
stimuli. Previous work has shown that activation by IL-12 and
IL-18 induces IL-22 in a heterogenous NK cell population (Wolk
et al., 2002). However, because IL-23 is a potent stimulator of
Th17 cells, has been previously shown to play a role in IL-22 ex-
pression of T cells, and is important in IBD pathogenesis, we also
examined whether this cytokine is able to induce IL-22.
IL-12 and IL-18 induced IL-22 mRNA and protein in NK cells,
but only in the CD27hi population (Figure 4). In contrast, IL-23
was able to induce IL-22 in both subsets, as well as in the ab-
sence of IL-18. Unlike IL-12 and IL-18, IL-23, with or without
A
B
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Figure 1. IL-22 Is Expressed in the Inflamed
Colon
(A) C57BL/6 CD4+ CD45RBhi CD25- NK1.1- T cells
(5 3 105) were transferred intraperitoneally to
Rag1/ mice, and 5 weeks after the transfer,
when clinical signs of IBD were evident, cytokine
mRNA in the colon was assessed by real-time
RT-PCR. As a control, cytokine in the colons of
Rag1/ mice that did not receive T cells was
also assessed. Bars represent the mean ± stan-
dard deviation (SD) ratio of cytokine gene to
HPRT expression as determined by the relative
quantification method (DDCT method). The exper-
iment was performed two times with similar re-
sults. There were five to seven mice/group. ND =
not detected.
(B) C57BL/6 CD4+ CD45RBhi CD25 NK1.1
T cells (5 3 105) were transferred intraperitoneally
to Rag1/ mice, and at different weeks after the
transfer (0, 1, 2, 3, and 4 weeks), cytokine mRNA
expressed in the colon was semi-quantitated by
real-time RT-PCR. Mean ± SD; dashed line indi-
cates limit of detection. There were four mice/
group.
(C) From the colon samples in (A), a 1 cm section of
the ascending colons of the above mice was
cultured ex vivo for 3 days. Secreted IFN-g (left)
or IL-22 (right) from the supernatants was quanti-
tated by ELISA; mean ± SD of 5–7 mice/group.
ND = not detected; dashed line indicates limit of
detection.Immunity 29, 947–957, December 19, 2008 ª2008 Elsevier Inc. 949
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Figure 2. IL-22 Protects the Colon during CD4 T Cell-Mediated Colitis
Il22+/+ or Il22/ CD4+ CD45RBhi CD25 NK1.1- T cells (5 3 105) were transferred intraperitoneally into Il22/ Rag1/ double-deficient mice.
(A) Mice were massed weekly, and the percent change from week 0 was calculated. Each dot represents one mouse bar indicates the mean, and crosses rep-
resent deadmice or mice that reached 30%mass loss and were euthanized according to protocol. For statistics, deadmice were assigned amass loss of30%.
An asterisk indicates a p value of < 0.05 determined by an unpaired two-tailed Student’s t test.
(B) Histology of H&E-stained sections from the ascending colons of the indicated mice, 3 weeks after the transfer. Shown are representative sections from one
mouse out of three to four mice/group. The bottom image is a higher magnification of the top image.
(C) At 4 weeks after the transfer, cytokine mRNA expression was assessed in the colons of the mice by real-time RT-PCR. Bars represent the mean ± SD
expression of the cytokine gene to HPRT using the DDCT method. ND = not detected. The experiment was performed two times with similar results.
(D) Total numbers of CD4+ TCRb+ cells in the inflamed colons as determined by FACS. Mean ± SD is shown.IL-18, was not able to induce IFN-g from either subset. Thus,
IL-22 can be differentially expressed; IL-22 can be expressed
by highly activated NK cells or from what are termed more inhib-
itory NK cells, under the proper stimulation conditions.
NK Cells Can Provide Protection during IBD
Unlike the role of T cells, the role of NK cells during IBD has
not been extensively studied. Therefore, we examined the co-
lons of mice with CD45RBhi-mediated colitis to see whether950 Immunity 29, 947–957, December 19, 2008 ª2008 Elsevier Inc.
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Figure 3. Rag1/ Mice Express Protective IL-22 during IBD
Il22+/+ or Il22/ CD4+ CD45RBhi CD25 NK1.1 T cells (5 3 105) were transferred i.p. into Rag1/ mice.
(A) Six-week-post-transfer expression of cytokine mRNA in the ascending colons of the mice was assessed by real-time RT-PCR. The cytokine gene message
was compared to that of HPRT via theDDCTmethod. Each dot represents onemouse, and the bar indicates themean. The experiment was performed three times
with similar results.
(B) Excised colon sections from either Rag1/ mice that did not receive transferred cells or Rag1/ mice that had received Il22/ T cells 6 weeks previously
were cultured for 3 days ex vivo, and then cytokine amounts in the supernatant were quantitated by ELISA. The bar indicatesmean ± SD; the dashed line indicates
the limit of detection.
(C) Mice from (A) were massed twice weekly, and the percent mass change from day 0 was calculated (top graph). At the same time, Il22+/+ or Il22/ CD4+
CD45RBhi CD25 NK1.1- T cells (53 105) were transferred intraperitoneally into Il22/ Rag1/mice, and their body mass was also monitored (bottom graph).
Points represent the mean percent change in body mass.NK cell-attracting chemokines were expressed, and if so,
whether NK cells were infiltrating the colon. We used reverse
transcriptase-polymerase chain reaction (RT-PCR) to examine
Rag1/ mice that had received IL-22 wild-type CD45RBhi
CD4+ T cells 2 weeks earlier and found that the chemokines
CXCL9, CXCL10, and CXCL11 were induced approximately 5-
to 10-fold more than they were in control mice (Figure 5A). By
FACS analysis, we found a population of NK1.1+ CD4- cells in
the inflamed colons of these mice (Figure 5B). In contrast, the
populations of colonic NK cells in nondiseased C57BL/6 mice
or Rag1/ mice were substantially smaller (Figure 5C). Thus,
NKcells appear to infiltrate the inflamedcolonand in thediseased
state constitute approximately 8%of the lymphocyte population.
To examine the relationship between NK cells and IL-22-medi-
ated protection during IBD, we performed CD45RBhi CD4+ T cellItransfers of IL-22 wild-type or IL-22-deficient cells into Rag2/
gc/ mice. Importantly, in addition to lacking all T cell subsets
because they lack both RAG and the signaling of several cyto-
kines (IL-2, IL-4, IL-7, IL-9, and IL-15) through the common
gamma chain (gc) receptor, these mice also lack NK cells (Cao
et al., 1995; DiSanto et al., 1995). As expected, transfer of
Il22+/+ T cells into Rag2/ gc/mice over the course of several
weeks led to IBD with increased amounts of both IFN-g and
IL-22 in the colons of these mice compared to those that did
not receive transferred cells (Figure 5C). The disease course
and its severity in the host Rag2/ gc/ mice was similar to
that observed in Rag1/mice. When Il22/ T cells were trans-
ferred into Rag2/ gc/mice, no IL-22 mRNA was detected in
their inflamed colons, although there was an approximately 100
fold-increase in IFN-g amounts in these mice compared tommunity 29, 947–957, December 19, 2008 ª2008 Elsevier Inc. 951
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IL-22 Protects from IBDRag2/ gc/ mice that did not receive cells (Figure 5D). IFN-g
amounts were similar to that observed to transfers into Rag1/
mice (Figure 2C). In addition, IL-22-secreted protein from ex
vivo-cultured colon tissue sections from these mice was not de-
tected by ELISA. We obtained similar results by performing
a similar experiment with the BALB/c strain of mice (data not
shown). These data strongly suggest that NK cells are a source
of IL-22 in the inflamed colon.
IL-22 Protects in a Model of Colitis Mediated
by the Innate Immune System
Colitis in humans is a complex interplay involving both the innate
and adaptive immune systems. Because IL-22 expression is not
limited to differentiated effector CD4+ T cells and can also be ex-
pressed by NK cells, we wished to determine whether IL-22
could also provide protection during colitis driven by the innate
immune system, as well as in the adaptive T cell model we pre-
sented above. One commonly employed model of innate colitis
is dextran sodium sulfate (DSS)-induced colitis (Cooper et al.,
1993;Mahler et al., 1998). In this model, DSS is given in the drink-
ing water and is thought to cause disruption of the epithelial in-
tegrity of the colon, and this disruption leads to inflammation
and colitis within one week. Like CD45RBhi-mediated transfer
IBD, this is primarily a disease of the colon. IL-22 mRNA is upre-
gulated in the colons of mice after DSS treatment (Brand et al.,
2006; te Velde et al., 2007). We confirmed that IL-22 protein se-
cretion is induced by DSS treatment when we detected IL-22 in
excised colon cultures of mice that received 3% DSS in their
drinking water for 3 days (Figure 6A). Because IL-22 is expressed
in the colon during DSS-induced colitis, we compared the dis-
ease courses of IL-22-deficient mice and wild-type control
mice. IL-22-deficient mice had lost significantly more mass by
day 8 after treatment than IL-22 wild-type mice (p = 0.0030)
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Figure 4. Differential Expression of IL-22
in Activated NK Cells by IL-23 or IL-12
NK1.1+ TCRb CD27lo (CD27lo) or NK1.1+ TCRb
CD27hi (CD27hi) NK cells were sorted from the
spleen and lymph nodes of C57BL/6 mice. Cells
were stimulated in vitro with IL-15 and the indi-
cated cytokines. Eighteen hours after stimulation,
IL-22 and IFN-g mRNA and protein expression
were analyzed by (A) real-time RT-PCR or (B)
ELISA of the supernatants, respectively. The ex-
periment was performed three times with similar
results.
(Figure 6B). In addition, IL-22-deficient
mice had a higher rate of mortality than
the wild-type mice (Figure 6C). Although
T cells have previously been shown have
little role in DSS-mediated colitis (Axels-
son et al., 1996; Dieleman et al., 1994),
we nevertheless also compared colitis in
Rag1/ mice and Il22/ Rag1/ mice
to rule out IL-22 expressed by T cells. As
observed for mice with T cells, RAG1-de-
ficient mice also deficient in IL-22 had
more severe disease than RAG1-deficient
mice (Figure S3). Thus, in addition to being protective during
adaptive-immune-mediated colitis, innate-immune-cell-driven
IL-22 is also protective during innate-immunity-mediated IBD.
To further provide evidence that NK cells are the primary in-
nate source of IL-22 in the colon during colitis, we used our in-
nate model of DSS-mediated colitis in the absence of T cells.
Three days after the initiation of DSS treatment, Rag1/ mice
were given either a depleting NK1.1 antibody or a control anti-
body. Twenty-four hours later, mice were euthanized, and IL-6
and IL-22 secretion from the colon was examined by ex vivo co-
lon culture. Colons from both sets of mice expressed compara-
ble levels of IL-6, indicating similar amounts of inflammation
(Figure 7A). However, the colons from the control antibody group
secreted significantly more IL-22 than those from mice that re-
ceived the NK1.1 depleting antibody (p = 0.0170) (Figure 7A).
Similar results were observed when NK cells were depleted in
Rag1/ mice via a different depleting reagent, anti-asialo GM1
antibody (Figure 7B). These data implicate NK cells as an innate
source of protective IL-22 in the inflamed colon.
DISCUSSION
IL-22 is a dual-natured cytokine; depending on the context of in-
flammation, it can have either inflammatory or protective proper-
ties. IL-22 has been shown to be an importantmediator in dermal
inflammation (Ma et al., 2008; Zheng et al., 2007), and alterna-
tively, it can provide protection to hepatocytes during liver in-
flammation (Radaeva et al., 2004; Zenewicz et al., 2007) and,
as we now show here, IBD. Th17 cells have also been termed in-
flammatory T cells because these cells are hypothesized to par-
ticipate in, if not instigate, inflammatory responses. IL-17A, the
original defining cytokine of this cell subset, is important for neu-
trophil recruitment and induction of antimicrobial peptides and,952 Immunity 29, 947–957, December 19, 2008 ª2008 Elsevier Inc.
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Figure 5. NK Cells Play a Role in IL-22-Me-
diated Protection during IBD
(A) NK-attracting chemokines are upregulated in
the colon during IBD. Two weeks after the transfer
of Il22+/+ CD4+ CD45RBhi CD25 NK1.1 T cells
(5 3 105) into Rag1/ mice or control Rag1/
mice that did not receive cells, mRNA amounts
of the chemokines Cxcl9, Cxcl10, and Cxcl11
were examined in the ascending colon by real-
time RT-PCR. Mean ± SD is shown.
(B) Il22/ CD4+ CD45RBhi CD25 NK1.1 T cells
(53 105) cells were transferred into Rag1/mice,
and 45 days after the transfer, when mice ex-
hibited clinical disease, colons were harvested
and stained by FACS for CD4 and NK1.1. Num-
bers indicate the mean ± SD percentage of CD4+
NK1.1 (top gate) or CD4NK1.1+ (right gate) cells
out of total lymphocytes isolated from the colon.
There were five mice/group.
(C) Total numbers of CD4+ T cells (CD4+ TCRb+)
and NK cells (NK1.1+ TCRb) in the colons of
mice presented in (B) as determined by FACS.
Mean ± SD is shown. B6 = C57BL/6 mouse,
ND = not detected.
(D) Il22+/+ or Il22/ CD4+ CD45RBhi CD25
NK1.1 T cells were transferred into Rag2/
gc/ mice (5 3 105 cells; intraperitoneally).
Forty-two days after the transfer, cytokine induc-
tion in the ascending colon was semi-quantitated
by real-time RT-PCR, as well as in untransferred
Rag2/ gc/ mice or C57BL/6 (B6) mice. Each
dot represents one mouse; the bar indicates the
mean; ND = not detected.like IL-22, is upregulated during chronic inflammatory diseases
such as IBD, rheumatoid arthritis, and psoriasis (Laan et al.,
1999; Liang et al., 2006) (Fujino et al., 2003; Kotake et al.,
1999). However, it is increasingly apparent that these cells do
not only promote inflammation but also have protective effects.
A recent study has put forward the idea, based on data from
many groups, that the Th17 subset is not a homogenous popu-
lation (McGeachy et al., 2007). In that study, based on the cyto-
kine milieu during differentiation, IL-17-expressing cells can be
inflammatory or protective depending of the coexpression of
IL-10. Additionally, multiple subpopulations defined by the ex-
pression of many of the Th17-related cytokines (IL-22, IL-21,
IL-17F, IL-6, TNFa) have been observed, and these distinct
expression patterns may represent functionally different cell
subsets.
CD4+ T cells, as well as NK T cells and gd T cells, all contribute
to IBD pathogenesis (Saubermann et al., 2000; Simpson et al.,
1997). The role of another lymphocyte subset, NK cells, has
not been as extensively studied in this context. NK cells provide
an innate immune defense mechanism that can be rapidly acti-
vated to secrete IFN-g and granzymes to quickly kill pathogen-
infected cells or cancerous cells. Because IFN-g is essential
for IBD development, NK cells could be hypothesized to contrib-
ute to this pathogenesis. However, although we have not ex-
cluded the possibility that they contribute to disease under other
circumstances, in the present study we have shown that NK cells
serve a protective role during IBD. We observed no difference incolitis in Rag1/ mice that received either IL-22 wild-type or
IL-22-deficient T cells. Moreover, Rag1/ mice that received
IL-22-deficient T cells surprisingly had high amounts of IL-22 in
their inflamed colons, indicating an innate immune source of
IL-22. Importantly, this innate IL-22 was protective. When
Il22/ Rag1/ double-deficient mice were used as hosts for
IBD experiments, mice that received IL-22-deficient T cells had
substantially greater disease than mice that received IL-22
wild-type T cells. Thus, the innate IL-22 in Rag1/ mice is
able to confer protection. Because NK cell expression of IL-22
had been previously reported, we examined IBD by using
Rag2/ gc/ mice as hosts; such mice differ from Rag1/
mice only in their absence of NK cells. Upon transfer of IL-22
deficient T cells, these mice did not express IL-22 in the inflamed
colon, whereas Rag1/ mice did; this provided compelling
evidence that NK cells are a source of IL-22. Further experiments
in which NK cells were depleted during innate-immune-medi-
ated colitis, in the complete absence of T cells, showed that
this depletion reduced amounts of IL-22 in the colon. Thus, NK
cells are an important source of IL-22, which protects the colon
during IBD.
A previous group showed that NK cells protect during a T cell-
mediated mouse model of IBD by performing NK-depletion ex-
periments during colitis; however, their data suggested that
this was due to direct effects of the NK cells on perforin produc-
tion by the activated T cells that mediated disease (Fort et al.,
1998). We now provide data showing that NK cells are an innateImmunity 29, 947–957, December 19, 2008 ª2008 Elsevier Inc. 953
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IL-22 Protects from IBDsource of IL-22 in the inflamed colon and that these cells contrib-
ute to the IL-22-mediated protection of the host tissues during
IBD. This effect is independent of effects on T cells, as shown
in the innate DSS colitis model. Furthermore, our study is a report
of a functional role attributed to IL-22 expression by NK cells, in-
stead of Th17 cells.
NK cell expression of IL-22 is differentially regulated between
subsets. Mature NK cells can be defined by surface expression
of CD27, a member of the TNFR super family. CD27hi cells have
a lower threshold for activation and express high amounts of cy-
tokines and granzymes, making them highly cytotoxic (Haya-
kawa et al., 2006). On the other hand, CD27lo cells have higher
expression of inhibitory receptors, and therefore their activation
is more strongly regulated. We show that IL-12 and IL-18 stimu-
lation can only induce IL-22 expression in CD27hi NK cells, but
not CD27lo cells. On the other hand, IL-23 is able to induce
IL-22 expression in both subsets, independently of IL-18, and
is unable to induce IFN-g. These distinct cytokine expression
patterns may allow for optimal immune responses while limiting
tissue damage during inflammation.
The cytokines of the IL-10-related cytokine family, with the ex-
ception of IL-10 itself, affect tissue responses and not the im-
mune system. IL-22 appears to be the most relevant cytokine
for the tissues comprising the gastrointestinal tract. IL-22R ex-
pression is greatest in the colon and small intestine when com-
pared to other tissues, such as the skin, where the predominant
IL-10 family member receptors are the IL-20Ra and IL-20Rb
chains. We also found that during IBD, IL-19 mRNA was not in-
duced in the colon, and we were unable to detect IL-20 tran-
scripts. In addition, we only observed Stat3 activation in colon
epithelial cells upon IL-22 stimulation, but not with IL-10, IL-19,
or IL-20. This is in agreement with previous studies showing
that IL-10 effects are limited to immune cells and that IL-19
and IL-20 function primarily in the skin (Blumberg et al., 2001;
Wolk et al., 2004; Wolk et al., 2005).
Stat3 is the main signaling pathway activated in responsive
cells upon stimulation with IL-10-related cytokines. IL-22 acti-
vates Stat3 in a wide variety of tissues, including keratinocytes,
hepatocytes, and as shown by us and other laboratories, colon
epithelial cells (Dumoutier et al., 2000; Wolk et al., 2004; Zene-
wicz et al., 2007). IL-22 has several different effects on the gas-
trointestinal epithelium. IL-22 can induce IL-6 and IL-8 secretion
from human colonocytes, as well as activate NF-kB and induc-
ible nitric oxide synthase (Andoh et al., 2005; Ziesche et al.,
2007). However, these proinflammatory effects on the gastroin-
testinal tract appear to be of limited effect in vivo. Overexpres-
sion of IL-22 in the colon leads to induction of mucus-associated
molecules, such as MUC1, MUC3, and MUC13, leading to en-
hanced mucus production due to the restitution of goblet cells
(Sugimoto et al., 2008). This might provide protection to the
colonic epithelium during inflammation by reducing the translo-
cation of commensal bacteria across the barrier. In addition,
IL-22 induces defensin expression in colonocytes, and these
antimicrobial peptides might also provide protection (Brand
et al., 2006).
One of the pitfalls with current therapies for chronic inflamma-
tion, such as TNFa inhibitors, is that they disrupt and weaken the
normal immune response and thus lead to increased disease
susceptibility. The benefit of an IL-22-mediated therapy may
be that the cytokine only signals to tissues and has no direct
effects on the immune response. This specific targeting should
allow modulation of tissue responses to alleviate tissue destruc-
tion during inflammation while having limited effects on the im-
mune response itself. IL-22 colon-targeted gene expression per-
formed by Sugimoto et al. has already shown that IL-22 holds
promise for IBD therapy (Sugimoto et al., 2008). Because IL-22
appears to be both proinflammatory and protective, caution
must be used in developing treatments based on this cytokine
or blocking its function with antibodies. In addition, IL-22 has
proliferative effects on cells (Radaeva et al., 2004), warranting
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Figure 6. IL-22 Also Provides Protection during Colitis Mediated
by the Innate Immune System
(A) IL-22 is secreted from the colon during DSS-mediated colitis. C57BL/6
mice either were given 3% DSS ad libitum in their drinking water or remained
untreated, and 3 days later themice were euthanized and their colons were ex-
cised. Colons were cultured for 3 days as described in the Experimental Pro-
cedures, and IL-22 was detected in the supernatant by ELISA. Bars represent
mean ± SD of seven mice/group.
(B) Il22+/+ or Il22/mice were given 3% DSS ad libitum in their drinking water
for 7 days. Mice were massed daily, and the percent mass change from day
0 was calculated. Mean ± SD is shown. An asterisk indicates a p value <
0.05. There were eight to ten mice/group.
(C) Survival of Il22+/+ or Il22/ mice in (B) after they received 3% DSS in their
drinking water.954 Immunity 29, 947–957, December 19, 2008 ª2008 Elsevier Inc.
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IL-22 Protects from IBDfurther studies to see whether continuous IL-22 stimulation al-
lows for tumor progression. Gaining a better understanding of
both the short-term and long-term effects of IL-22 on different
tissues is needed to enable the development of IL-22-related
therapeutics for chronic inflammatory diseases such as IBD.
EXPERIMENTAL PROCEDURES
Mice
IL-22-deficient mice were as previously described (Zenewicz et al., 2007).
Mice used were at generation 10 of a backcross to the C57BL/6 strain. Mice
within experiments were sex and age matched. Rag1/ mice (The Jackson
aboratory; Bar Harbor, ME) and Rag2/ gc-/ mice (Taconic Farms; Hudson,
NY) were bred in-house. The progeny of a cross of Il22/ mice to Rag1/
mice were intercrossed to generate Il22/ Rag1/ double-knockout mice
that, upon genetic screening, were then breed as Il22/ Rag1/ 3 Il22/
Rag1/. All mice were cared for in accordance with protocols established
by the institutional animal care and use committee at the Yale University animal
facility.
CD45RBhi Transfers
Splenocytes and inguinal and axillary lymph nodes from Il22+/+ or Il22/mice
were CD4 MACS (Miltenyi Biotech; Auburn, CA) purified, and naive CD4+
T cells were further purified by FACS sorting so that a population of cells
that were CD4+ CD45RBhi CD25 NK1.1 was collected. A total of 5 3 105
cells were transferred intraperitoneally into the indicated recipient mice
(Rag1/, Il22/Rag1/, or Rag2/gc/). Mice were massed twice
a week and euthanized when they had lost 30% of their initial mass.
DSS-Induced Colitis
Mice were given 3% dextran sodium sulfate (DSS) (molecular weight: 36,000-
50,000) (MP Biomedicals, Inc.; Solon, OH) ad libitum in their drinking water for
7 days. Body mass was measured every 24 hr, and mice were euthanized
when they had lost 30% of their initial mass. Where indicated, mice were given
250 mg of anti-NK1.1 (PK136), 250 mg of control IgG2a, or 500 mg of anti-asialo
GM1 (SH-34) (all from BioXCell, West Lebanon, NH) intraperitoneally.
Lymphocyte Preparation and Flow Cytometry
Colons were removed from euthanized mice, placed into Bruff’s media, and
passed through a wire-mesh screen. In brief, colon homogenate was incu-
bated with 100 U/ml collagenase (Sigma; St. Louis, MO) and 20 mg/ml DNase
Control IgG2a NK1.1 Ab
0
500
1000
1500
2000
2500
3000
3500
IL
-
22
 (p
g/m
l)
No treatment Asialo GM1 Ab
0
500
1000
1500
2000
2500
3000
3500
IL
-
22
 (p
g/m
l)
Control IgG2a NK1.1 Ab
0
1000
2000
3000
4000
5000
6000
IL
-
6 
(pg
/m
l)
No treatment Asialo GM1 Ab
0
1000
2000
3000
4000
5000
6000
IL
-
6 
(pg
/m
l)
A B
* *
Figure 7. NK Cell Depletion Decreases IL-
22 Expression in the Inflamed Colon
Rag1/ mice were given 3% DSS ad libitum in
their drinking water for 4 days. On the third day,
mice were either untreated or intraperitoneally
injected with (A) 250 mg of NK1.1-depleting anti-
body or control IgG2a or (B) 500 mg asialo GM1
antibody. Twenty-four hours later, mice were eu-
thanized, and colons were excised. Colons
were cultured for three days as described in the
Experimental Procedures, and IL-22 or IL-6 was
detected in the supernatant by ELISA. Each dot
represents one colon segment, bars represent
the mean of four to five mice/group; there are
four segments per mouse. An asterisk indicates
p < 0.05. The experiment was performed twice
with similar results.
I (Sigma) for 40 min at 37C. For removal of colonic
debris, homogenates were centrifuged at 300 rpm
for 3 min, and then supernatants were centrifuged
at 1500 rpm for 10 min. The cells were resus-
pended in 1 ml complete media and 4 ml of 30%
OptiPrep (Axis-Shield; Oslo, Norway) in a sodium phosphate buffer, and
1 ml of media was carefully layered on top. Cells were centrifuged at
2700 rpm for 20 min. The top layer and interface were harvested as the lym-
phocyte population. Cells were stained with fluorescently conjugated anti-
bodies in 1% BSA in PBS and fixed in 2% PFA. Cells were analyzed with
a FACSCalibur (BD Biosciences; San Jose, CA), and data were analyzed by
FlowJo v. 6.1 (TreeStar, Inc., Ashland, OR).
Real-Time RT-PCR
RNA from cells or organs was isolated with Trizol reagent (Invitrogen; Carls-
bad, CA). RNA was subjected to reverse transcriptase with Superscript II (In-
vitrogen) and oligo dT primer. cDNA was semi-quantitated with commercially
available primer and probe sets (Applied Biosystems; Foster City, CA) and the
DDCT method. Hypoxanthineguanine phosphoribosyltransferase (HPRT) was
included as an internal control.
Ex Vivo Colon Culture and ELISAs
Sections of 1 cm of the ascending colon were excised, removed of feces,
washed three times with sterile PBS, and then longitudinally halved. The colon
sections were then placed into culture in complete Bruff’s media (10% FBS,
L-glutamine, penicillin, streptomycin, and tetracycline) and cultured at 37C
with 5% CO2. Supernatants were harvested after 3 days, and the concentra-
tion of cytokine was determined by ELISA. IFN-g and IL-6 ELISA (BD PharMin-
gen; San Diego, CA) or IL-22 ELISA (Antigenix America; Huntington Station,
NY) were performed according to the manufacturer’s protocols.
NK Cell Stimulation
Spleens and lymph nodes were isolated from C57BL/6 mice and prepared as
described previously (Zenewicz et al., 2007), and NK1.1+ TCRb- CD27 lo or
NK1.1+ TCRb- CD27 hi cells were sorted on a FACS Aria. The cells were
stimulated in vitro with the indicated combination of the following cytokines:
50 ng/ml IL-15 (Peprotech; Rocky Hill, NJ), 50 ng/ml IL-12 (BD PharMingen),
50 ng/ml IL-23 (eBioscience; San Diego, CA), and 20 ng/ml IL-18 (MPL;
Naka-ku Nagoya, Japan) for 18 hr or remained untreated. mRNA was har-
vested, and cytokine expression was semiquantitated by real-time RT-PCR
as described above.
Detection of Activated Stat3
Caco-2 cells (ATCC HTB-37) were grown in DMEM media supplemented with
20% FBS, 2 mM glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin.
Cells were stimulated for 20 min with the indicated concentration of recombi-
nant human IL-10, IL-19, IL-20, or IL-22 (all from Peprotech). Cell lysates wereImmunity 29, 947–957, December 19, 2008 ª2008 Elsevier Inc. 955
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IL-22 Protects from IBDseparated under reducing conditions on 4% to 12% gradient gel with the
NuPAGE electrophoresis system (Invitrogen). Gels were transferred to Immo-
bolin P membrane (Millipore; Billerica, MA), blocked with 5% dry milk in PBS
with 0.01% Tween. Blots were then incubated overnight at 4C with one of
the following primary antibodies: anti-phospho-Stat3 Tyr705 (polyclonal) or
anti-Stat3 antibody (polyclonal) (both from Cell Signaling Technology; Dan-
vers, MA). Blots were washed, incubated with appropriate secondary anti-
bodies conjugated to horse radish peroxidase, and then developed with
chemiluminescent substrate (Pierce, Rockford, IL) and film.
Histology
Organs were removed and fixed in 4% paraformaldehyde overnight at 4C,
then embedded in paraffin, sectioned, and stained with H&E. Slides were pre-
pared at the Yale University Program for Critical Technologies in Molecular
Medicine, Department of Pathology.
Statistics
Prism 4.03 software (Graphpad Software; San Diego, CA) was used for statis-
tical analyses. p values of less than 0.05 were considered statistically signifi-
cant.
SUPPLEMENTAL DATA
Supplemental Data include three figures and are available with this article
online at http://www.immunity.com/supplemental/S1074-7613(08)00507-4.
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